Cucurbitacin IIACAS# 58546-34-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 58546-34-2 | SDF | Download SDF |
| PubChem ID | 181183 | Appearance | White powder |
| Formula | C32H50O8 | M.Wt | 562.73 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Synonyms | 25-Acetoxy 23,24-dihydrocucurbitacin F; 25-O-Acetyl 23,24-dihydrocucurbitacin F; Cucurbitacin IIa; Dihydrocucurbitacin F 25-O-acetate; Dihydrocucurbitacin Q1 | ||
| Solubility | Soluble in methan | ||
| Chemical Name | [(6R)-6-hydroxy-2-methyl-5-oxo-6-[(2S,3S,8S,9R,10R,13R,14S,16R,17R)-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-11-oxo-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptan-2-yl] acetate | ||
| SMILES | CC(=O)OC(C)(C)CCC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3CC(C(C4(C)C)O)O)C)C)C)O)O | ||
| Standard InChIKey | LKYNAQSYQLFTCM-GYXNDICUSA-N | ||
| Standard InChI | InChI=1S/C32H50O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,19-22,25-26,34-35,38-39H,11-16H2,1-9H3/t19-,20+,21-,22+,25+,26-,29+,30-,31+,32+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cucurbitacin IIa has anti-cancer, anti-bacterial, and anti-inflammatory effects, it can induce apoptosis and enhance autophagy; it also can disrupt the actin cytoskeleton and direct the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3. |
| Targets | Caspase | NF-kB | TNF-α | PARP | JAK | STAT | MAPK |
| In vitro | Cucurbitacin IIa induces caspase-3-dependent apoptosis and enhances autophagy in lipopolysaccharide-stimulated RAW 264.7 macrophages.[Pubmed: 23541744]Int Immunopharmacol. 2013 May;16(1):27-34.Cucurbitacin IIA (CuIIa), a member of cucurbitacin family, is isolated from the root of Hemsleya amabilis which has been used as an ancient remedy for bacillary dysentery and gastroenteritis. The anti-inflammatory properties of Cucurbitacin IIA have long been recognized but the underlying mechanism is largely unknown. |
| Kinase Assay | Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.[Pubmed: 21304528]Br J Cancer. 2011 Mar 1;104(5):781-9.Cucurbitacin (Cuc) and triterpene-derived natural products exhibit anti-cancer potential in addition to their conspicuous anti-bacterial and anti-inflammatory activity. Recently, inhibition of Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling was shown to underlie the effects of Cuc family on inducing cell death in cancer. |
Cucurbitacin IIA Dilution Calculator
Cucurbitacin IIA Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7771 mL | 8.8853 mL | 17.7705 mL | 35.541 mL | 44.4263 mL |
| 5 mM | 0.3554 mL | 1.7771 mL | 3.5541 mL | 7.1082 mL | 8.8853 mL |
| 10 mM | 0.1777 mL | 0.8885 mL | 1.7771 mL | 3.5541 mL | 4.4426 mL |
| 50 mM | 0.0355 mL | 0.1777 mL | 0.3554 mL | 0.7108 mL | 0.8885 mL |
| 100 mM | 0.0178 mL | 0.0889 mL | 0.1777 mL | 0.3554 mL | 0.4443 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Rebaudioside B
Catalog No.:BCN2612
CAS No.:58543-17-2
- Rebaudioside A
Catalog No.:BCN5900
CAS No.:58543-16-1
- (-)-Cephaeline dihydrochloride
Catalog No.:BCN8323
CAS No.:5853-29-2
- Pseurotin A
Catalog No.:BCN7246
CAS No.:58523-30-1
- IOX 1
Catalog No.:BCC6192
CAS No.:5852-78-8
- ent-16beta,17-Isopropylidenedioxykaurane
Catalog No.:BCN1408
CAS No.:58493-71-3
- Olvanil
Catalog No.:BCC6855
CAS No.:58493-49-5
- Lemannine
Catalog No.:BCN3742
CAS No.:58480-54-9
- Platycodin D
Catalog No.:BCN4982
CAS No.:58479-68-8
- Ferrugine
Catalog No.:BCN1910
CAS No.:58471-11-7
- Darlingine
Catalog No.:BCN1906
CAS No.:58471-10-6
- N-(2-Hydroxy-4-methoxyphenyl)acetamide
Catalog No.:BCN1409
CAS No.:58469-06-0
- Gomisin A
Catalog No.:BCN5794
CAS No.:58546-54-6
- Schisantherin B
Catalog No.:BCN1023
CAS No.:58546-55-7
- Schisantherin A
Catalog No.:BCN1024
CAS No.:58546-56-8
- Confluentin
Catalog No.:BCN5795
CAS No.:585534-03-8
- Losmapimod
Catalog No.:BCC5368
CAS No.:585543-15-3
- Saikosaponin B1
Catalog No.:BCN5917
CAS No.:58558-08-0
- Saikosaponin B4
Catalog No.:BCN8516
CAS No.:58558-09-1
- Anagrelide HCl
Catalog No.:BCC2306
CAS No.:58579-51-4
- m-Anisic acid
Catalog No.:BCC9015
CAS No.:586-38-9
- H- ß-HoGlu-OH.HCl
Catalog No.:BCC3232
CAS No.:58610-41-6
- Boc-ON
Catalog No.:BCC2797
CAS No.:58632-95-4
- PH-797804
Catalog No.:BCC3672
CAS No.:586379-66-0
Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.[Pubmed:21304528]
Br J Cancer. 2011 Mar 1;104(5):781-9.
BACKGROUND: Cucurbitacin (Cuc) and triterpene-derived natural products exhibit anti-cancer potential in addition to their conspicuous anti-bacterial and anti-inflammatory activity. Recently, inhibition of Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling was shown to underlie the effects of Cuc family on inducing cell death in cancer. METHOD: We purified Cuc IIa, the active component from the medicinal plant Hemsleya amalils Diels, which shows different structural modifications from other Cuc derivatives. We investigated the mechanisms of its inhibitory effects on cancer cells in vitro and tumour growth in vivo. RESULTS: Cuc IIa induced the irreversible clustering of filamentous actin and arrested cell cycle by the increases in G2/M populations. Cuc IIa resulted in the reduced phospho-Histone H3 and markedly increased cleavage of poly-(ADP-ribose) polymerase or PARP, immediate upstream of DNA breakdown as the result of caspase activation, consistent with mitotic blockage-induced cell death. However, unlike other Cuc members, Cuc IIa did not suppress JAK2/STAT3 phosphorylation or alter phosphorylation of mitogen-activated protein kinases. Instead, the expression of the cell cycle-regulated Inhibitor of Apoptosis Protein (IAP) survivin was reduced. Introducing oncoprotein delta-catenin, which increased survivin expression and suppressed small GTPase RhoA, reduced efficacy of Cuc IIa to induce cell death. Supporting the effects of Cuc IIa on actin cytoskeletal signaling, RhoA phosphorylation was reduced suggesting its increased activity. CONCLUSION: Cuc IIa is a novel class of anti-cancer drug in suppression of cancer cell expansion by disrupting the actin cytoskeleton and directing the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3.
Cucurbitacin IIa induces caspase-3-dependent apoptosis and enhances autophagy in lipopolysaccharide-stimulated RAW 264.7 macrophages.[Pubmed:23541744]
Int Immunopharmacol. 2013 May;16(1):27-34.
Cucurbitacin IIA (CuIIa), a member of cucurbitacin family, is isolated from the root of Hemsleya amabilis which has been used as an ancient remedy for bacillary dysentery and gastroenteritis. The anti-inflammatory properties of CuIIa have long been recognized but the underlying mechanism is largely unknown. In this study, we investigated the anti-inflammatory effect of CuIIa on lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage cells. The results showed that CuIIa inhibited the proliferation and migration of RAW 264.7 cells in a dose-dependent manner. Whereas CuIIa did not cause apoptosis in unstimulated RAW 264.7 cells, it did induce a significant apoptosis in LPS-stimulated cells, which was caspase-3-dependent and associated with downregulation of survivin. Furthermore, LPS induced autophagy in RAW 264.7 cells and this effect was further enhanced by CuIIa as evidenced by increased levels of LC3-II conjugates and formation of LC3 puncta. In addition, CuIIa disrupted actin cytoskeleton via inducing actin aggregation. However, neither the synthesis of tumor necrosis factor-alpha, nor the activation of the mitogen-activated protein kinases and NF-kappaB pathways in LPS-stimulated cells was suppressed by CuIIa treatment. Collectively, these results suggested that induction of apoptosis and enhancement of autophagy contributed to the anti-inflammatory activity of CuIIa against inflammation-related diseases.
